Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Total Current Liabilities: 2023-2024

Historic Total Current Liabilities for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Dec 2024 value amounting to $156.9 million.

  • Monte Rosa Therapeutics' Total Current Liabilities rose 47.55% to $61.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.4 million, marking a year-over-year increase of 47.55%. This contributed to the annual value of $156.9 million for FY2024, which is 236.85% up from last year.
  • As of FY2024, Monte Rosa Therapeutics' Total Current Liabilities stood at $156.9 million, which was up 236.85% from $46.6 million recorded in FY2023.
  • Over the past 5 years, Monte Rosa Therapeutics' Total Current Liabilities peaked at $156.9 million during FY2024, and registered a low of $46.6 million during FY2023.
  • For the 2-year period, Monte Rosa Therapeutics' Total Current Liabilities averaged around $101.8 million, with its median value being $101.8 million (2023).
  • Data for Monte Rosa Therapeutics' Total Current Liabilities shows a peak YoY skyrocketed of 236.85% (in 2024) over the last 5 years.
  • Over the past 2 years, Monte Rosa Therapeutics' Total Current Liabilities (Yearly) stood at $46.6 million in 2023, then skyrocketed by 236.85% to $156.9 million in 2024.